AbbVie: VIEKIRA PAK Achieves 95% Sustained Virologic Response Rates In TOPAZ-II

(RTTNews) - AbbVie (ABBV) announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), with or without ribavirin, in adult patients with genotype 1a or genotype 1b chronic hepatitis C virus infection. The company said the results show that 95 percent of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment after 12 or 24 weeks of treatment, a secondary endpoint for the study.

TOPAZ-II is an ongoing Phase 3b multicenter study in the U.S. evaluating the safety and efficacy of 12 or 24 weeks of treatment with VIEKIRA PAK, with or without ribavirin, in treatment-naïve or pegIFN/RBV treatment-experienced, adult patients with GT1 chronic HCV infection with or without compensated cirrhosis.

Paritaprevir was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.